Soon it won’t be possible to fund the huge enterprises of the leading pharma companies with a handful of blockbuster drugs. The only question is whether they can change and innovate in time.
It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.
Politicians are great gamblers – but the EC President is playing for high stakes by wagering all on the creation of a European Institute of Technology.
Innovation policy is hot in Brussels, says Science|Business editor Richard L. Hudson. Hot enough for so a confusing array of proposals, white papers, conferences and task forces.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.